Toxoplasma gondii infection in the peritoneal macrophages of rats treated with glucocorticoids

Wang, T, Gao, J, Yi, SQ, Geng, GQ, Gao, XJ, Shen, JL, Lu, FL, Wen, YZ, Hide, G and Lun, ZR

http://dx.doi.org/10.1007/s00436-013-3661-3

<table>
<thead>
<tr>
<th>Title</th>
<th>Toxoplasma gondii infection in the peritoneal macrophages of rats treated with glucocorticoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authors</td>
<td>Wang, T, Gao, J, Yi, SQ, Geng, GQ, Gao, XJ, Shen, JL, Lu, FL, Wen, YZ, Hide, G and Lun, ZR</td>
</tr>
<tr>
<td>Type</td>
<td>Article</td>
</tr>
<tr>
<td>URL</td>
<td>This version is available at: <a href="http://usir.salford.ac.uk/id/eprint/33377/">http://usir.salford.ac.uk/id/eprint/33377/</a></td>
</tr>
<tr>
<td>Published Date</td>
<td>2014</td>
</tr>
</tbody>
</table>

USIR is a digital collection of the research output of the University of Salford. Where copyright permits, full text material held in the repository is made freely available online and can be read, downloaded and copied for non-commercial private study or research purposes. Please check the manuscript for any further copyright restrictions.

For more information, including our policy and submission procedure, please contact the Repository Team at: usir@salford.ac.uk.
Toxoplasma gondii infection in the peritoneal macrophages of rats treated with glucocorticoids

Tao Wang · Jiang-Mei Gao · Si-Qi Yi · Guo-Qing Geng · Xiao-Jie Gao · Ji-Long Shen · Fang-Li Lu · Yan-Zi Wen · Geoff Hide · Zhao-Rong Lun

T. Wang · J.-M. Gao · S.-Q. Yi · G.-Q. Geng · X.-J. Gao · Y.-Z. Wen · Z.-R. Lun

Center for Parasitic Organisms, State Key Laboratory of Biocontrol, School of Life Sciences and Key Laboratory of Tropical Disease Control of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510275, China

e-mail: lsslzr@mail.sysu.edu.cn

J.-L. Shen

Department of Parasitology and The Key Laboratories of Pathogen Biology and Zoonoses, Anhui, Anhui Medical University, Hefei 230032, China

F.-L. Lu

Department of Parasitology and Key Laboratory of Tropical Disease Control of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China
G. Hide · Z.-R. Lun

Ecosystems and Environment Research Centre and Biomedical Research Centre, School of Environment and Life Sciences, University of Salford, Salford, M5 4WT, UK

T. Wang

Department of Parasitology, School of Basic Medical Sciences, Jiujiang University, Jiujiang 332000, China
Abstract It is well known that toxoplasmosis can be life-threatening to immunocompromised individuals such as AIDS and organ transplantation patients. Glucocorticoids (GCs) are widely used in the clinic for the treatment of autoimmune diseases and organ transplantation resulting in acute toxoplasmosis in these patients. However, the interaction and mechanism between the development of acute toxoplasmosis and GC therapy are still unknown. The aims of this study were to investigate the infection of *T. gondii* in the peritoneal macrophages of rats treated with glucocorticoids. Our results showed that the growth rate of *T. gondii* RH strain was significantly increased in the peritoneal macrophages of rats treated with glucocorticoids *in vivo*. For instance, 242 (±16) tachyzoites were found in 100 macrophages from the rats treated with methylprednisolone (MP), while only 16 (±4) tachyzoites were counted in the macrophages from the non-treated control rats 24 hrs after infection (*P*<0.01). We also demonstrated that a significant inhibition of nitric oxide (NO) production was detected in the macrophages collected from the rats post-treated with GCs with 12.90 µM (±0.99 µM) of nitrite production from the rats treated with MP, while 30.85 µM (±1.62µM) was found in the non-treated control rats 36 hrs after incubation (*P*<0.01). Furthermore, glucocorticoids could significantly inhibit the expression of inducible nitric oxide synthase mRNA and its protein in the rat peritoneal macrophages. Our results strongly indicate that the decrease of NO in the rat peritoneal macrophages is closely linked to the cause of acute toxoplasmosis in the host. Additionally, there was a significant increase in the number of cysts produced by the naturally cyst forming, *T. gondii* Prugniaud strain with an average of
2795 (±422) cysts of the parasite being detected in the brains of the rats treated with dexamethasone, while only 1356 (±490) cysts were found in the non-treated control animals \((P<0.01)\). As rats and humans are both naturally resistant to \(T. gondii\) infection, these novel data could lead to a better understanding of the development of acute toxoplasmosis during glucocorticoid therapy in humans.

Introduction

As one of the most severe opportunistic infectious diseases, toxoplasmosis caused by \(T. gondii\) is life-threatening to immunocompromised patients with AIDS, cancer and those who are under immunosuppressant treatment following transplantation. A high mortality rate has been documented in immunocompromised patients due to severe toxoplasmosis (caused by the re-activation of chronic infection) (Montoya and Liesenfeld, 2004). However, the association between immunosuppression using glucocorticoids and the occurrence of severe toxoplasmosis is not well understood (Chandrasekar and Momin, 2003; De-Medeiros et al. 2001).

Glucocorticoids (GCs) are important modulators of immune cell functions (Sternberg, 2006). Due to their well-known immunosuppressive and anti-inflammatory properties, synthetic GCs are widely used in clinical practice and are effective in the treatment of autoimmune disease (Sathasivam, 2008), immunological rejection (Everson et al. 2003), atopic inflammatory disease (Tarpataki, 2006) and acute critical illness (Minneci et al. 2004; Rady et al. 2006).

It has also been well documented that GCs can mediate immune responses by
affecting viability and function of various important immune cells including macrophages, B cells, monocytes and granulocytes (Chen et al. 2010; Tsianakas et al. 2012). Amongst these cells, macrophages are considered the most ubiquitous in mammalian tissues and play a central role in both innate and acquired immune responses.

Activated macrophages acquire competence for enhanced anti-microbial activity including nitric oxide (NO) production (Cape and Hurst, 2009; Severin et al. 2010; Silva, 2010). NO is recognized as a major regulatory molecule of the immune system and a principal cytotoxic mediator of activated immune effector cells which plays a critical role against pathogen infections (Adams et al. 1990; Li et al. 2012).

However, what is still not clear is the relationship between the effects of GCs on the function of macrophages and the development of acute toxoplasmosis from chronic infections. Infection of humans, with *T. gondii*, usually shows a chronic profile which is similar to that found in rats (Sumyuen et al. 1996; Da-Silva et al. 2010; Dubey, 2011; Li et al. 2012). Therefore, the rat model has been suggested to be an ideal model to study the development of acute toxoplasmosis from chronic infection in humans. The aims of this study were to understand the effect of GCs on the infection of rat peritoneal macrophages with the *T. gondii* RH strain and the effect on cyst formation of the naturally cyst forming *T. gondii* Prugniaud strain in the brains of rats treated with GCs. Results from this work will provide useful data to better understand human toxoplasmosis from the individuals who were treated with GCs.
Materials and methods

Animals and parasites

Special pathogen free Sprague Dawley (SD) rats weighing from 180 to 220 g were used for the source of peritoneal macrophages and BALB/c mice used for the maintenance of the *T. gondii* RH were purchased from the experimental animal center of Guangdong province, China. Special pathogen free F344 rats were purchased from Vital River Laboratories (Beijing, China). BALB/c mice were intraperitoneally (i.p.) inoculated with $1 \times 10^6$ tachyzoites of *T. gondii* RH-GFP (Nishikawa et al. 2003).

Tachyzoites were harvested and isolated from the infected animals and were resuspended in RPMI-1640 medium supplemented with 10% FBS. *T. gondii* Prugniaud strain was maintained in NIH mice. Cysts were isolated from the brains of infected animal when they were required. Protocols for the use of animals were approved by the Institutional Review Board of Animal Care of Sun Yat-Sen University (973 project, #2010CB530000).

Peritoneal macrophage isolation and cultivation

Methods for isolation of macrophages from GC treated and non-treated rats were used as previously described (Li et al. 2012; El-Mahmoudy et al. 2002). The pelleted peritoneal macrophages were resuspended in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and penicillin (100 U/ml) after washing. Final concentrations of $2 \times 10^5$ cells in 200 µl and of $5 \times 10^6$ cells in 2.5 ml were seeded into each well in 96- and 6-well tissue culture plates (Corning, USA) respectively and
were incubated at 37°C, 5% CO₂, 95% air for 2 hrs. The macrophages were then carefully washed three times with FBS free RPMI-1640 medium to remove the non-adherent cells and incubated with the test compounds indicated in the results.

Animal treatments

For the experimental treatment with GCs, 8 rats in each of four groups were used in this study. In the control group, each rat was intramuscularly (i.m.) injected with 0.2 ml saline solution, while in the other three groups, each animal was intramuscularly injected with dexamethasone (DXM), hydrocortisone sodium succinate (HSS) and methylprednisolone (MP) at 1.5 mg/kg/d, 20 mg/kg/d and 20 mg/kg/d respectively for 7 days (Da-Silva et al. 2010; Dimitriu et al. 2008).

T. gondii infection in macrophages collected from rats treated with GC

The macrophages harvested from the rats treated with GCs mentioned above, were challenged with tachyzoites at a ratio of tachyzoite/macrophage of 1:1 at 12 hrs post incubation. Extracellular tachyzoites were then washed out after 1 hr of contact with macrophages and the time was then defined as 1 hr. The macrophages were continuously cultured in RPMI-1640 contained FBS and penicillin. Macrophages were observed under an inverted fluorescent microscope at 1, 12 and 24 hrs and the numbers of cells infected with T. gondii as well as the number of parasites per 100 macrophages were counted. Controls were carried out using the macrophages collected from the non-GC treated rats using an identical protocol.
Measurement of nitrite concentration

The NO production was evaluated indirectly by measuring nitrite concentration in macrophage cultural supernatants as described previously (Green et al. 1982; Li et al., 2012). Supernatant (150 µl) was collected from each well at intervals of cultivation and mixed with an equal volume of Griess reagent on a 96-well flat-bottomed plate (Corning, USA). Absorbance at 540/550 nm was measured in an ELISA reader.

Nitrite concentration was calculated based on a standard curve using sodium nitrite diluted with the same medium used for the cultivation of macrophages.

RNA extraction and assessment of iNOS mRNA expression by reverse transcription polymerase chain reaction (RT-PCR)

Total RNA from macrophages collected from rats treated or non-treated with GCs were extracted using Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. Total RNA was reversed to cDNA using a set of oligo (dT) primer and Super Script™ III First-Strand Synthesis System (Invitrogen, Carlsbad, USA) and the cDNA (1 µl) was used as template for amplification of iNOS and GAPDH gene (used as internal standard) by PCR with the following primers:

iNOS, 5’-CTA CCT ACC TGG GGA ACA CCT GGG-3’ and 5’-GGA GGA GCT GAT GGA GTA GTA GCG G-3’, producing a fragment of 442 bp; GADPH, 5’-AAT GCK TCC TGY ACC AAC TGC-3’ and 5’-TTA GCC AWA TTC RTT GTC RTA CCA GG-3, producing an amplified fragment at 513 bp. The PCR products were
analyzed by agarose gel electrophoresis.

Expression analysis of iNOS by western blotting

Cells were lysed in SDS loading buffer, fractionated in SDS-PAGE and transferred onto the immunoblot polyvinylidene difluoride membrane (Pall, USA). The membrane was probed using the rabbit polyclonal iNOS antibody (Thermo, USA) (Santa Cruz, USA). β-tubulin was detected with anti-β-tubulin antibody (NOVUS, USA) as a control. Horseradish peroxidase-labeled secondary antibodies (Cell Signaling, USA) and a DAB (3,3’,5,5’-tetramethylbenzidine) Detection Kit (Tiangen, China) were used for antibody detection.

Infection of *T. gondii* Prugniaud strain in F344 rats treated with or without GC

Twenty F344 rats were used in this experiment. Each animal was infected by feeding 300 cysts of the *T. gondii* Prugniaud strain. They were randomly divided into two groups. Animals in Group I were treated with DXM (2 mg/kg/every two days), while rats in Group II (control) were treated with PBS only. Animals in the groups were treated with DXM or PBS for 4 weeks starting after infection. All animals were sacrificed two months after infection and cysts were counted from the homogenized brain tissue of each rat. The reason that DXM was chosen for this work was this compound is more commonly used in the clinic than other compounds.

Statistical analysis
All data were obtained from the experiments repeated at least three times and were shown as the mean ± S.D. Statistical analysis of the data for multiple comparisons was performed by one-way ANOVA. $P<0.05$ was considered statistically significant and $P<0.01$ was considered highly significant.

**Results**

Replication of *T. gondii* RH strain in the peritoneal macrophages of rats treated with GCs

Table 1 shows the replication of *T. gondii* RH strains tachyzoites in the peritoneal macrophages isolated from the rats injected intramuscularly with GCs (dexamethasone, DXM; hydrocortisone sodium succinate, HSS and methylprednisolone, MP). A difference in infection rate was not found across all 4 groups at 1 hr post infection. However, significant differences were observed between the GC treated and non-GC treated group at 12 and 24 hrs post infection ($P<0.01$).

An example fluorescent micrograph demonstrating the presence of more tachyzoites in the macrophages of rats treated with DMX than in those from the non-treated control rats is shown in Figure 1B and 1D (at 1 and 24hrs). Similar results were also observed in the macrophages collected from rats treated with HSS and MP respectively (data not shown).

Nitrite production in the peritoneal macrophages of rats treated with GCs

The effect of GCs on NO production by peritoneal macrophages from rats was
determined by the measurement of nitrite concentration in cell culture supernatants as a reliable marker for NO production. As shown in Table 2, by comparison to the non-treated control, a significantly lower NO production was detected in the peritoneal macrophages collected from the rats treated with GCs for 7 days \((P<0.01)\).

Synergistic effects of *T. gondii* infection and GC treatment on NO production in rat peritoneal macrophages

Table 3 shows the synergistic effect on the production of NO by rat peritoneal macrophages when they were treated with GCs *in vivo* and infected with *T. gondii* *in vitro*. Significantly less NO production was detected in the peritoneal macrophages of rats treated with GCs and infected with *T. gondii* than that found in GC treatment or *T. gondii* infection only \((P<0.01)\). These results indicate that GC treatment and *T. gondii* infection may have a synergistic effect on inhibiting NO production in the rat peritoneal macrophages.

The mRNA expression and protein levels of iNOS in the peritoneal macrophages of rats treated with GCs

Figure 2(A) shows the analysis of iNOS mRNA levels of the peritoneal macrophages of rats treated with GCs by RT-PCR. The size of PCR products was estimated at the correct size of 442 bp. Band intensities show lower levels of iNOS expression in the peritoneal macrophages of rats treated with GCs. Figure 2(B) displays the analysis of iNOS protein levels in the peritoneal macrophages of rats treated with GCs as
determined by Western blotting. Lower expression levels of iNOS were detected in the peritoneal macrophages treated with GCs. Down-regulation of iNOS expression by GC treatment was consistent with the reduction in nitrite level in the culture supernatants from these macrophages.

Effects of DXM on cyst burden of the *T. gondii* Prugniaud strain in the brains of F344 rats

The Prugniaud strain of *T. gondii* is a type II strain and more readily forms cysts in rodent brains than the type I RH strain. Figure 3 shows the number of cysts found in the brains of F344 rats infected with the *T. gondii* Prugniaud strain and treated with DXM. An average of 2795±422 cysts was found in the brain tissues from the rats treated with DXM, while only 1356±490 cysts were detected from the control rats. This result clearly indicated that DXM could significantly increase the number of cysts in the brains of rats treated with this GC (*P*< 0.01). Although obvious differences in clinical signs were not observed between these two groups of rats, the significant increase in cysts found in the brain of the rats treated with DXM clearly demonstrates the effect of DXM on *T. gondii* cysts in F344 rats.

Discussion

Human infection with *T. gondii* can be obtained by ingestion of oocysts from contaminated food and water, by eating undercooked or raw meat containing cysts and by congenital transmission (Dubey, 2011). After the acute stage of disease
(tachyzoites), the parasite develops cysts (bradyzoites, latent stage) in a variety of organs, but mainly in the brain and skeletal muscle cells, and establishes a chronic infection (Lang et al. 2007). Immunosuppression found in AIDS, cancer and organ transplantation patients can cause the reactivation of a latent infection resulting in acute infection (Sibley, 1993; Skariah et al. 2010). Additionally, it has been suggested that natural immunosuppression associated with pregnancy may also result in reactivation of maternal infection followed by congenital transmission (Hide et al. 2009; Thomasson et al. 2011). However, little is known about the mechanism of the reactivation of chronic infection of T. gondii within mammalian hosts although weaker immunity has been suggested to be linked to such reactivation (Chandrasekar and Momin, 2003; De-Medeiros et al. 2001).

It is reported that the peritoneal macrophages of rat are naturally resistant to T. gondii infection (Dubey, 2011) and recent studies have demonstrated that the mechanism of such resistance is strongly linked to higher expression of inducible nitric oxide synthase (iNOS) in the rat peritoneal macrophage (Li et al. 2012). Interestingly, however, lower expression of iNOS was found in alveolar macrophages of rat and they were demonstrated to be more sensitive, than those from the peritoneal cavity, to infection with T. gondii RH strain (Zhao et al. 2013). GCs are known to regulate the immunological reactions, mediate many aspects of homeostasis and play a critical role in the systemic stress response. The powerful anti-inflammatory and immunosuppressive properties of GCs have also made them an extremely valuable therapy in patients with severe inflammatory and autoimmune disorders (Everson et al.
Therefore, we propose that GCs might decrease NO production in rat peritoneal macrophages since it has been shown that the long term use of GCs in mammalian hosts (rodents and humans) can result in the development of acute toxoplasmosis from chronic infection (Montoya and Liesenfeld, 2004; De-Medeiros et al. 2011). Understanding these mechanisms will greatly improve our knowledge of the reasons why and how long term use of GCs in mammalian hosts including humans, can cause acute toxoplasmosis.

In this study, we have adopted three GC agents that are all widely used in the clinic and each has a physiological half-life and pharmacodynamic action. Our results further support previous studies (Li et al. 2012) that *T. gondii* cannot multiply efficiently in the normal rat peritoneal macrophages, but surprisingly we found that it could grow well in the peritoneal macrophages of rats treated with GCs. Furthermore, our results showed that the growth of *T. gondii* in the rat peritoneal macrophages was linked to the reduction of NO production in macrophages treated with GCs. These results are consistent with the results by Li and colleagues (Li et al. 2012) that they demonstrated that a lower concentration of NO in the rodent peritoneal macrophages is strongly linked to their susceptibility to *T. gondii* infection.

Some studies demonstrated that *T. gondii* infection could decrease NO production in the peritoneal macrophages (Nishikawa et al. 2007) and it was suggested as one of the reasons for the development of acute toxoplasmosis from chronic infection. Our results also showed that *T. gondii* infection could partially decrease NO production in the infected cells which was suggested as one of the
pathways used by the parasite to enable to escape the immune reaction in the host (Seabra et al. 2002). However, we consider that it may not be the key reason for the development of acute toxoplasmosis from chronic infection. Our data showed that the synergistic interaction between *Toxoplasma* infection and GC treatment may be an important driver for this transition. Based on the above analysis, it is reasonable to propose that the down-regulation of NO could be a shared and generic mechanism that could explain why macrophage resistance to *T. gondii* infection or control of *Toxoplasma* activation is impaired during GC treatment.

Furthermore, we demonstrated that GCs could inhibit the expression of iNOS mRNA and protein in rat peritoneal macrophages by RT-PCR and western-blotting analysis. These data are supported by the results from previous studies which demonstrated that DXM could inhibit the expression of iNOS in human hepatocytes and alveolar macrophages (Geller et al. 1993; Xiang et al. 2000). Because of the tremendous differences in iNOS activity between the peritoneal macrophages from mice and rats (Li et al. 2012), the bias towards studies in mouse models needs to be augmented with further studies on rats.

A key question that needs to be addressed is: what is the mechanism of NO action that drives the transition from acute toxoplasmosis to the chronic infection? NO is beneficial in minimizing pathogenesis in the host during chronic toxoplasmosis (Hayashi et al. 1996; Scharton-Kersten et al. 1997). In the absence of NO, chronically infected rats and mice could develop lethal disease with increased *T. gondii* burden and severe inflammation in the places where the parasites were located (Bohne et al.
Some studies have shown that NO may serve as a molecular trigger for stage conversion of *T. gondii* tachyzoites to bradyzoites leading to a state of chronic infection in the host (Bohne et al. 1994). In most cases, *T. gondii* causes asymptomatic infection in healthy individuals. However, GCs as immunosuppressive agents could change the immune status of the host resulting in the development of acute toxoplasmosis from a chronic infection (Djurkovic-Djakvoic and Milenkovic, 2001). Our work demonstrated that GCs significantly reduced the synthesis of NO in rat peritoneal macrophages which is similar to the effect of these compounds on the hepatocytes of rats (Geller et al. 1993) and alveolar macrophages of humans (Xiang et al. 2000). Furthermore, these studies provide novel data which could enable a better understanding of the generation of acute toxoplasmosis.

Rats have long been considered the species of choice as a model for human toxoplasmosis on account of the similarity of their resistance to *T. gondii* infection with that found in humans (Derouin et al. 1995; Freyre et al. 2003; Dubey, 2011), although much less work has been done than in the mouse model. It has been demonstrated that activated rat peritoneal macrophages can markedly inhibit the multiplication of *T. gondii* *in vitro* (Zhao et al. 2009). Cellular immunity appears to be crucial in the control of *Toxoplasma* infection in mammalian hosts and, in particular, the role of activated macrophages has been emphasized (Suzuki et al. 1988). Our results showed that GCs have an enhancing effect on the growth of *T. gondii* *in vitro* in rat peritoneal macrophages which further demonstrates the important role of NO in macrophages in causing the host to be naturally resistant to *T. gondii* infection.
Interestingly, a recent study has revealed that acute toxoplasma infection also increases endogenous production of GCs (Kugler et al. 2013). From the parasite perspective and based on our observations, this mechanism may serve to promote further parasite growth. From the host perspective, Kugler et al (2013) show that this endogenous GC production serves to invoke a CD4+ T cell response which they propose limits collateral tissue damage and improves host survival. Our data would support the role of GC dependent NO reduction in the parasite side of this host-parasite evolutionary arms race.

In addition, our results demonstrated that significantly more *T. gondii* cysts (Prugniaud strain) were found in the brains of rats treated with the glucocorticoid dexamethasone (DXM). This result was consistent with our expectation. We consider that the treatment of rat peritoneal macrophages with GCs causes changes in some important physiological functions, for instance, a lower concentration of NO which provides a suitable environment for the growth and multiplication of *T. gondii*. This also potentially explains why acute infection of *T. gondii* is frequently found in human patients treated with GCs.

In conclusion, we have analyzed possible mechanisms of the effect of GCs on the resistance of rat peritoneal macrophages to *T. gondii* infection. These results not only provide useful novel data for better understanding the protective mechanisms of the host against this parasite but also reveal, indirectly, that patients who have been administered with GCs following organ transplantation could potentially provide *T. gondii* with a good opportunity to generate a new infection.
Acknowledgments The authors are thankful to Dr. X.N. Xuan for providing Toxoplasma gondii RH-GFP strain. The work was supported by National Basic Research Program of China (973 Program) (No. 2010CB530000), http://www.973.gov.cn/English/Index.aspx.

References


Chandrasekar PH, Momin F (1997) Disseminated toxoplasmosis in marrow recipients, a report of three cases and a review of the literature. Bone Marrow Transplant 19(7): 685-689


infection in chronically infected rats (*Rattus norvegicus*). Exp Parasitol 125(4):

409-412


Geller DA, Nussler AK, Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, Simmons
RL, Billiar TR (1993) Cytokines, endotoxin, and glucocorticoids regulate the
expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci
USA 90(2): 522-526

Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982)
Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem
126(1): 131-138

the host parasite equilibrium in toxoplasmosis. J Immunol 156(4): 1476-1481

Hide G, Morley EK, Hughes JM, Gerwash O, Elmahaishi MS, Thomasson D, Wright
EA, Williams RH, Murphy RG, Smith JE (2009) Evidence for high levels of

Kugler DG, Mittelstadt PR, Ashwell JD, Sher A, Jankovic D (2013) CD4+ T cells are
trigger and target of the glucocorticoid response that prevents lethal

responses by Toxoplasma gondii. Parasitol Res 100(2): 191-203

Li Z, Zhao ZJ, Zhu XQ, Ren QS, Nie FF, Gao JM, Gao XJ, Yang TB, Zhou WL, Shen
iNOS and arginase expression and activity in the macrophages of rats are
responsible for the resistance against T. gondii infection. PLoS One 7(4): e35834

the effect of steroids on survival and shock during sepsis depends on the dose.


Thomasson D, Wright EA, Hughes JM, Dodd NS, Cox AP, Boyce K, Gerwash O, Abushahma M, Lun ZR, Murphy RG, Rogan MT, Hide G (2011) Prevalence and coinfection of *Toxoplasma gondii* and *Neospora caninum* in *Apodemus sylvaticus* in an area relatively free of cats. Parasitology 138(9): 1117-1123


Table 1 Proliferation of *T. gondii* in peritoneal macrophages of rats treated with GCs.

<table>
<thead>
<tr>
<th>GCs</th>
<th>Number of <em>T. gondii</em>/100 cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 h</td>
</tr>
<tr>
<td>DXM</td>
<td>35±3</td>
</tr>
<tr>
<td>HSS</td>
<td>39±5</td>
</tr>
<tr>
<td>MP</td>
<td>37±6</td>
</tr>
<tr>
<td>Control</td>
<td>39±5</td>
</tr>
</tbody>
</table>

SD rats were injected intramuscularly with a dose of GCs for 7 days, macrophages were harvested and cultured for 12 hrs and then incubated with *T. gondii* at the ratio of 1:1 (parasites/macrophages = 1:1). The extracellular *T. gondii* were washed from the medium after 1 hr contact and the time was defined as 1 hr and the number of parasites per 100 macrophages was counted at 1, 12 and 24 hrs after infection. *: *P*<0.01 vs. control analyzed by one-way ANOVA. All values are expressed as the mean ± S.D of each infected group mice (X±SD, n=3). Abbreviations: dexamethasone (DXM), hydrocortisone sodium succinate (HSS) and methylprednisolone (MP).
Table 2 Nitrite production by peritoneal macrophages from rats treated with GCs.

<table>
<thead>
<tr>
<th>GCs</th>
<th>12 h</th>
<th>24 hrs</th>
<th>36 hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXM</td>
<td>9.78±0.37*</td>
<td>14.31±1.22*</td>
<td>17.99±1.08*</td>
</tr>
<tr>
<td>HSS</td>
<td>8.19±0.32*</td>
<td>11.05±0.74*</td>
<td>13.51±1.45*</td>
</tr>
<tr>
<td>MP</td>
<td>7.86±0.46*</td>
<td>10.65±0.98*</td>
<td>12.90±0.99*</td>
</tr>
<tr>
<td>Control</td>
<td>14.44±1.04</td>
<td>25.41±1.44</td>
<td>30.85±1.62</td>
</tr>
</tbody>
</table>

Peritoneal macrophages isolated from rats treated with GCs for 7 days were incubated for 12, 24 and 36 hrs. NO₂⁻ production in the supernatant of the cell culture medium, a reflection of NO production, was measured by the Griess reaction. *: P<0.01 vs. control analyzed by one-way ANOVA (X±SD, n=3).
Table 3 Nitrite production by peritoneal macrophages isolated from rats injected intramuscularly with GCs and subsequent infection with *Toxoplasma gondii*.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Nitrite production (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 h</td>
</tr>
<tr>
<td>DXM+<em>T. gondii</em></td>
<td>7.70±0.79*</td>
</tr>
<tr>
<td>HSS+<em>T. gondii</em></td>
<td>6.37±0.97*</td>
</tr>
<tr>
<td>MP+<em>T. gondii</em></td>
<td>6.7±0.99*</td>
</tr>
<tr>
<td>Control+<em>T. gondii</em></td>
<td>12.02±1.12#</td>
</tr>
<tr>
<td>Control</td>
<td>15.97±1.41</td>
</tr>
</tbody>
</table>

SD rats were injected intramuscularly with a dose of GCs for 7 days (see details in the Materials and Methods). Peritoneal macrophages collected from the treated rats, were cultured for 12 hrs and were then challenged with *T. gondii* *in vitro*. At 12 hrs and 24 hrs after infection, NO$_2^-$ production in the supernatants was measured by the Griess reaction.*: *P<0.01 vs. control+*T. gondii*; #: *P<0.05;* the comparison between control+*T. gondii* and control was analyzed by one-way ANOVA. All values are expressed as the mean ± S.D of each infected group mice (X±SD, n=3).
Figure legends:

**Fig. 1** Fluorescent micrographs of *Toxoplasma gondii* proliferation in the macrophages of rats treated with DXM.

Macrophages collected from SD rats treated with DXM for 7 days and were cultured *in vitro* for 12 hrs before challenge with *T. gondii* tachyzoites at a ratio of *T. gondii* macrophage of 1:1. A and B: *T. gondii* in the normal control SD rat macrophages; and C and D: *T. gondii* infection in the peritoneal macrophages of SD rats treated with DXM. Similar results were also found in the macrophages of rats treated with HSS and MP (Data not shown) (Scale is 50 µm)
Fig. 2 Comparison of iNOS expression levels from the peritoneal macrophages of rats treated with GCs.

Macrophages collected from SD rats treated with GCs for 7 days and were cultured in vitro for 12 hrs. (A) RT-PCR analysis for the expression of iNOS mRNA. (B) Western blotting analysis for the expression of iNOS protein.
Fig. 3 Effect of DXM on the cyst burden of the *T. gondii* Prugniaud strain in the brain of F344 rats.

Cyst burden from the brains of F344 rats infected with the Prugniaud (Pru) strain of *T. gondii* and treated (B) and non-treated (A) with DXM. * indicates a significance value of $P < 0.05$. 

![Diagram showing cyst burden comparison between treated and non-treated groups.](image-url)